When to Start Population-Wide Screening for Chronic Kidney Disease: A Cost-Effectiveness Analysis

ABSTRACT:

Importance

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have changed clinical management of chronic kidney disease (CKD) and made populationwide screening for CKD a viable strategy. Optimal age of screening initiation has yet to be evaluated.

Objective

To compare the clinical benefits, costs, and cost-effectiveness of population-wide CKD screening at different initiation ages and screening frequencies.

Design, setting, and participants

This cost-effectiveness study used a previously published decision-analytic Markov cohort model that simulated progression of CKD among US adults from age 35 years and older and was calibrated to population-level data from the National Health and Nutrition Examination Survey (NHANES). Effectiveness of SGLT2 inhibitors was derived f

SUBMITTER: Cusick MM 

PROVIDER: S-EPMC11549659 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature